Research Study to Look at How Well Semaglutide Works in People Living With Heart Failure, Obesity and Type 2 Diabetes
NCT04916470 on ClinicalTrials.gov · last registry update 2025-11-26
Finished 11 October 2023, after enrolling 617 people. Primary outcome, as filed: Change in KCCQ (Kansas City Cardiomyopathy Questionnaire) clinical summary score. semaglutide is approved in the US, but not for heart failure — a registration here is not an approval, and most drugs tested in a new condition never get one for it.
- Status
- COMPLETED
- Phase
- P3
- Drug
- semaglutideOzempic, Rybelsus, Wegovy
- Sponsor
- Novo Nordisk A/S
- Sponsor type
- Industry
- Enrollment
- 617
- Started
- 2021-06-15
- Primary completion
- 2023-10-11 actual
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
Change in KCCQ (Kansas City Cardiomyopathy Questionnaire) clinical summary score
Conditions studied
Heart Failure With Preserved Ejection Fraction (HFpEF) and Diabetes Mellitus, Type 2
Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.